
Please try another search
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. Its ALA-101 product entered first-in-human phase 1 clinical trial. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Name | Age | Since | Title |
---|---|---|---|
Michael Baker | - | 2020 | CEO, MD & Director |
Anastasios Karadimitris | - | - | Chairman of Scientific Advisory Board |
Debora Barton | 48 | 2021 | Member of Clinical Advisory Board & Independent Non-Executive Director |
Reuben Benjamin | - | 2021 | Member of Scientific Advisory Board |
John Maher | - | 2021 | Member of Scientific Advisory Board |
Salvatore Fiorenza | - | 2024 | Chair of Clinical Advisory Board |
Gary Jonathan Phillips | 64 | 2022 | Independent Non-Executive Director |
Sattva S. Neelapu | - | 2024 | Member of Clinical Advisory Board |
Gianpietro Dotti | - | 2024 | Member of Scientific Advisory Board |
Elizabeth Stoner | 75 | 2021 | Independent Non-Executive Interim Chairperson |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review